Exploring the diversity of cancer-associated fibroblasts: insights into mechanisms of drug resistance

Introduction

Cancer-associated fibroblasts (CAFs) constitute a pivotal cellular component within the tumor microenvironment (TME), exerting multifaceted regulatory roles in tumorigenesis and disease progression (Ping et al., 2021). Diverging from their quiescent counterparts, CAFs are predominantly localized within the stromal compartment surrounding tumors, characterized by distinct phenotypic and functional attributes. These aberrant fibroblasts actively participate in extracellular matrix (ECM) remodeling, fostering a permissive milieu for tumor cell proliferation and dissemination, while concurrently modulating key signaling cascades implicated in oncogenic processes (Ping et al., 2021).

The clinical significance of CAFs is underscored by their association with adverse prognostic outcomes across diverse cancer types, signifying their potential as prognostic biomarkers (Min et al., 2021; Mak et al., 2022; Xu et al., 2023). Their intricate interplay with cancer cells and stromal constituents not only influences tumor behavior but also dictates therapeutic responses, often facilitating the emergence of chemoresistance. A comprehensive understanding of the reciprocal crosstalk between CAFs and tumor cells has thus prompted endeavors to devise targeted therapeutic interventions aimed at disrupting tumor-stroma interactions, with CAFs emerging as promising targets for circumventing therapeutic resistance and augmenting treatment efficacy (Zhang et al., 2023).

Nevertheless, the heterogeneity inherent to CAF populations poses a formidable challenge in delineating their precise functional roles and devising tailored therapeutic strategies (Zhang et al., 2023). Recent advancements in single-cell transcriptomic profiling, notably through technologies such as single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics, have unveiled a spectrum of CAF subpopulations characterized by distinct gene expression profiles, functional attributes, and spatial distribution within the TME (Zhang et al., 2020; Kieffer et al., 2020; Wang et al., 2021; Hu et al., 2022; Luo et al., 2022; Liu et al., 2023; Cords et al., 2023). These discrete CAF subsets exhibit nuanced phenotypic characteristics and exert context-dependent effects on tumor progression, necessitating a nuanced approach towards therapeutic targeting.

In this review, we systematically interrogate the landscape of CAF heterogeneity by leveraging scRNA-seq data encompassing diverse malignancies. In total, we reviewed and systematized data from 36 scRNA-seq studies, encompassing 17 types of human malignant tumors (Elyada et al., 2019; Zhang et al., 2020; Chen et al., 2020; Dominguez et al., 2020; Kieffer et al., 2020; Lin et al., 2020; Wang et al., 2021; Zhang et al., 2021; Che et al., 2021; Chen et al., 2021; Galbo et al., 2021; Hornburg et al., 2021; Olbrecht et al., 2021; Pu et al., 2021; Li et al., 2022; Bischoff et al., 2022; Li et al., 2022; Chen et al., 2022; Li et al., 2022; Deng et al., 2022; Giguelay et al., 2022; Hu et al., 2022; Loret et al., 2022; Luo et al., 2022; Obradovic et al., 2022; Yang et al., 2022; Zhao et al., 2022; Liu et al., 2023; Qin et al., 2023; Liu et al., 2023; Zhang et al., 2023; Cords et al., 2023; Ma et al., 2023; Pan et al., 2023; Wang et al., 2023; Werba et al., 2023). As a result, we identified and characterized three primary CAFs populations: myofibroblast-like CAFs, inflammatory CAFs, and antigen-presenting CAFs. We delineated their unique gene signatures, which allows to distinguish each CAF population from other CAFs and TME cells. Notably, our findings elucidate previously overlooked genes implicated in CAF function, thereby enriching our understanding of CAF biology. Additionally, we discussed the presence of rare CAF subtypes characterized in only a few studies.

Furthermore, we scrutinize the role of distinct CAF subpopulations in mediating tumor resistance to conventional and targeted therapeutic modalities. By elucidating the differential impact of CAF heterogeneity on treatment responses, we emphasize the need to integrate CAF profiling into therapeutic decision-making processes. Our synthesis not only underscores the complexity of the TME but also informs the rational design of anti-CAF therapies tailored to target specific tumor-promoting CAF populations, thereby heralding a paradigm shift towards precision medicine in cancer therapeutics.

Heterogeneity of CAFs

Recent studies have unveiled the heterogeneous nature of CAFs, shedding light on the existence of diverse cellular populations within this entity (Sugimoto et al., 2006; Öhlund et al., 2017). This diversity for the first time was noted by the identification of two distinct subpopulations of CAFs within breast and pancreatic carcinomas, distinguished by the expression patterns of the S100A4 gene (Sugimoto et al., 2006). Further investigations, both in vitro and in vivo, have underscored the complexity of CAFs, revealing spatially separated, phenotype reversible, and mutually exclusive subtypes within co-cultures of murine pancreatic stellate cells, the main source of CAFs within pancreatic cancer, and pancreatic ductal adenocarcinoma organoids (Öhlund et al., 2017).

However, elucidating the specific subtypes of CAFs in tumor tissues, alongside their unique transcriptional characteristics, remained challenging until the emergence of scRNA-seq technologies. Despite limitations inherent to scRNA-seq, such as its reduced sensitivity to transcripts with low expression levels, this approach offers unparalleled advantages in dissecting the heterogeneity of tissue cell populations (Zhang et al., 2021).

Unlike traditional methods, scRNA-seq analysis eliminates the necessity to pre-isolate fibroblast populations using specific protein markers. Instead, it enables a comprehensive analysis of all cellular constituents within tissues. Additionally, it overcomes obstacles associated with cell culturing, which has been shown to potentially alter CAF phenotype over prolonged periods (Fuyuhiro et al., 2011; Wang et al., 2015; Sahai et al., 2020; Ping et al., 2021). For example, gastric CAFs had increased expression of standard CAF marker ACTA2 compared to normal fibroblasts at the third passage, but by the eighth passage, they did not demonstrate significant difference in the expression of this gene (Fuyuhiro et al., 2011). Thus, scRNA-seq emerges as a practical alternative for exploring CAF heterogeneity.

For a long time, CAFs were believed to consist only of two distinct populations: myofibroblasts-like CAFs (myCAFs) and inflammatory CAFs (iCAFs) (Sugimoto et al., 2006; Öhlund et al., 2017). With the advent of scRNA-seq, the existence of multiple phenotypically and functionally distinct CAF populations has become apparent (Figure 1) (Galbo et al., 2021; Cords et al., 2023; Ma et al., 2023). Currently, there is growing evidence supporting the existence of another CAF population in each tumor type—antigen-presenting CAFs (apCAFs) (Figure 1) (Zhang et al., 2020; Kieffer et al., 2020; Wang et al., 2021; Hu et al., 2022; Luo et al., 2022; Liu et al., 2023; Cords et al., 2023). Moreover, scRNA-seq studies have identified other rarely occurring CAF populations in the microenvironment of different tumor types (Figure 1) (Zhang et al., 2020; Galbo et al., 2021; Li et al., 2022; Cords et al., 2023; Ma et al., 2023). The characteristics of each CAF subpopulation will be further discussed in detail.

Figure 1. Heterogeneity of cancer-associated fibroblasts (CAFs) and their markers. myCAFs, myofibroblasts-like CAFs; iCAFs, inflammatory CAFs; apCAFs, antigen-presenting CAFs; pCAFs, proliferative CAFs; ifnCAFs, interferon-response CAFs; meCAFs, metabolic CAFs; EMT-like CAFs, epithelial to mesenchymal transition-like CAFs; tCAFs, tumor-like CAFs; rCAFs, reticular-like CAFs; vCAFs, vascular CAFs.

Myofibroblasts-like subtype of cancer-associated fibroblasts—myCAFs

Gene signature of myCAF

Initially, myCAFs were discerned from pancreatic ductal adenocarcinoma, delineated as contractile matrix-producing fibroblasts (FAP+ αSMAhigh CAFs), showcasing heightened expression of ACTA2 and TGFβ response genes including CTGF and COL1A1 (Öhlund et al., 2017). The advent of scRNA-seq has uncovered a similar fibroblast phenotype across diverse solid human tumors. However, transcriptional profiles attributed to myCAFs exhibit variations across studies. Broadly, myCAFs characterization via scRNA-seq can be grouped into two categories.

In the first category, myCAFs are distinguished as a distinct cell population typified by elevated expression of the blood vessel wall gene RGS5, contractility genes (MYH11, ACTA2, TAGLN, MYL9), and other pericyte markers (NDUFA4L2, ADIRF) (Elyada et al., 2019; Chen et al., 2020; Galbo et al., 2021; Pu et al., 2021; Li t al., 2022; Chen et al., 2022; Hu et al., 2022; Luo et al., 2022; Obradovic et al., 2022; Yang et al., 2022; Zhao et al., 2022; Liu et al., 2023; Qin et al., 2023). Functionally, these cells are implicated in processes such as angiogenesis, smooth muscle contraction, and vascular wound healing. Apart from being referred to as myCAFs, they are also labeled as contractile CAFs (Che et al., 2021; Giguelay et al., 2022), stellate-like CAFs (Wang et al., 2021), MCAM+ CAFs (Wang et al., 2023), RGS5+ CAFs (Olbrecht et al., 2021; Zhang et al., 2023) and MYH11+ CAFs (Olbrecht et al., 2021). However, evidence suggests that a similar transcriptional profile is characteristic of pericytes and other mural cells (van Splunder et al., 2024). Consequently, several scRNA-seq investigations propose categorizing this population as pericytes rather than fibroblasts (Lin et al., 2020; Zhang et al., 2021; Bischoff et al., 2022; Li et al., 2022; Cords et al., 2023; Werba et al., 2023). Furthermore, scRNA-seq analysis of normal muscular organs discerned a 90-gene signature capable of distinguishing fibroblasts from mural cells (Muhl et al., 2020). Consistent with this, heightened expression of genes including MYL9, MYH11, MCAM, TAGLN, and ACTA2 suggests affiliation with mural cells. This raises the question: does a distinct population of RGS5 + MYH11+ CAFs truly exist or they should be considered as pericytes or other mural cells? Recent studies suggest that the analysis of scRNA-seq data allows to separate these two similar types of cells within tumors: pericytes and vascular CAFs (vCAFs), likely originating from vascular cells (Cords et al., 2023). Notably, vCAFs, akin to pericytes, exhibit elevated expression of angiogenesis-related genes (MYH11, ACTA2, MCAM, and ADIRF) (Cords et al., 2023). However, RGS5 gene expression is much lower in vCAFs compared to pericytes. Similar to pericytes, vCAFs localize around endothelial cells within vascular structures. Nevertheless, accurate classification of all RGS5 + MYH11+ cell populations is imperative for further exploration of vascular tumor cells and CAFs.

The second category of myCAFs, also termed as such in studies, is typified by expression of collagen-encoding genes (COL1A1, COL10A1, COL11A1, CTHRC1, etc.), matrix metalloproteinases (MMP11), non-collagenous ECM genes (POSTN, THBS2, and VCAN, FN1), and signal transduction genes (SULF1, INHBA) (Kieffer et al., 2020; Lin et al., 2020; Wang et al., 2021; Bischoff et al., 2022; Loret et al., 2022; Liu et al., 2023; Werba et al., 2023). These fibroblasts, also referred to as matrix CAFs (mCAFs) (Zhang et al., 2020; Cords et al., 2023; Ma et al., 2023), ECM-remodeling CAFs (Che et al., 2021; Giguelay et al., 2022), desmoplastic CAFs (dCAFs) (Galbo et al., 2021), TGF-β-activated CAFs (TGFB CAFs) (Hornburg et al., 2021), classical CAFs (cCAFs) (Chen et al., 2021), and others (Olbrecht et al., 2021; Deng et al., 2022; Pan et al., 2023), are intricately associated with ECM organization and remodeling, collagen production, TGF-β response and pathways governing the epithelial to mesenchymal transition (EMT). Studies suggest that these fibroblasts arise from resident fibroblasts and are localized within collagen-rich regions of the tumor (Bartoschek et al., 2018; Zhang et al., 2020; Cords et al., 2023). The upregulation of genes linked to TGF-β-induced reactive stroma implies a pivotal role for TGF-β in activating resident fibroblasts and shaping the myCAF phenotype (Bates et al., 2015; Biffi et al., 2019; Kieffer et al., 2020; Hornburg et al., 2021; Giguelay et al., 2022). Importantly, TGF-β1-activated fibroblasts accelerate cancer cell motility and invasion (Yeung et al., 2013; Huang et al., 2021; Yoon et al., 2021). The localization of matrix-associated myCAFs at the invasive tumor front further underscores their role in tumor invasion (Zhang et al., 2020).

The variability in characteristics among myCAFs contributes to ambiguity when comparing results across different studies. Hence, caution is warranted in analyzing the RGS5+MYH11+ cell population within tumors, emphasizing the necessity to confirm whether this population represents pericytes. Given that the term myCAFs was initially coined for fibroblasts capable of producing a collagen matrix, we propose categorizing the second group of cells as myCAFs.

Prognostic potential of myCAFs markers

The expression of markers characteristic of myCAFs serves as a distinguishing feature among various CAF populations. However, the specificity of this gene signature to myCAFs amidst all tumor cell populations remains a subject of inquiry. scRNA-seq studies indicate that the expression of most myCAFs marker genes is primarily confined to fibroblasts within the tumor milieu (Lambrechts et al., 2018; Elyada et al., 2019; Chen et al., 2020; Wang et al., 2021; Zhang et al., 2021; Che et al., 2021; Olbrecht et al., 2021; Pu et al., 2021; Luo et al., 2022; Zhao et al., 2022; Qin et al., 2023; Zhang et al., 2023; Ma et al., 2023; Wang et al., 2023; Werba et al., 2023). Furthermore, analysis of immunohistochemistry staining (IHC) images from the Human Protein Atlas database (Uhlen et al., 2017) reveals predominant localization of proteins such as COL3A1, POSTN, VCAN, FN1, COL12A1 in the stroma of solid tumor types (Supplementary Figure S1). These findings suggest that the myCAF gene signature is not characteristic of any other cell population within the tumor and its microenvironment. Consequently, alterations in the expression of this gene signature in tumor tissues likely reflect changes in the abundance of the myCAF population.

According to bulk RNAseq analyses, myCAF markers are predominantly upregulated at transcriptional level in tumor tissues compared to normal tissues across various cancer types (Figure 2; Supplementary Table S1). These observations are further substantiated at the protein level through comparisons of IHC staining patterns in tumor and normal tissues (Figure 2; Supplementary Table S1). Notably, the myCAF gene signature exhibits a significant correlation with poor survival outcomes among patients diagnosed with stomach adenocarcinoma, kidney carcinoma, mesothelioma, low-grade glioma, cervical squamous cell carcinoma, bladder urothelial carcinoma, skin cutaneous melanoma, lung carcinoid tumors and prostate cancer (Galbo et al., 2021; Bischoff et al., 2022; Liu et al., 2023; Pan et al., 2023). Furthermore, elevated expression of most myCAFs marker genes correlates with poor overall survival across various cancer types (Figure 2; Supplementary Table S2). Thus, the heightened presence of the myCAF population emerges as a characteristic feature of tumor tissues and is associated with an unfavorable prognosis.

Figure 2. Changes in the expression and prognostic significance of myofibroblast-like cancer-associated fibroblasts (myCAFs) markers across different types of tumors. Red indicates increased expression of the gene/protein in the tumor compared to normal tissue, blue indicates decreased expression, and purple indicates both increased and decreased expression observed in different studies. A cross symbol indicates an association of increased gene expression with poor prognosis, while a checkmark indicates an association with good prognosis.

Contribution of myCAFs to the development of chemoresistance

The myCAF population plays a pivotal role within the tumor stromal microenvironment, actively participating in the remodeling of the ECM, a process intricately linked to the development of chemoresistance. One such modification characteristic of tumor tissues is ECM stiffening, primarily caused by the increased deposition of type I collagen and fibronectin (Cox and Erler, 2011). These proteins are coded by genes COL1A1, COL1A2, and FN1, primarily expressed in myCAFs. This stiffening of the ECM poses significant challenges to effective capillary transport of therapeutic agents into tumor tissues, owing to the resultant elevation in interstitial fluid pressure (Figure 3) (Stylianopoulos et al., 2018). Furthermore, myCAF-mediated ECM stiffness serves as a driver of angiogenesis, further fueling tumor progression (Figure 3). Inhibition of fibroblast activity using renin-angiotensin system inhibitors results in decreased ECM stiffness and enhances the anti-angiogenic effects of bevacizumab in patients with metastatic colorectal cancer (Shen et al., 2020). Notably, in various cancers such as pancreatic and breast cancer, the heightened ECM stiffness contributes to resistance against chemotherapeutic agents like paclitaxel and doxorubicin, respectively, through the induction of EMT processes (Figure 3) (Rice et al., 2017; Joyce et al., 2018). Moreover, the rigidity of the ECM may be linked to the regulation of DNA double-strand break repair processes, thereby influencing cellular sensitivity to genotoxic agents, including etoposide and cisplatin (Deng et al., 2020). In breast cancer cells growing on low stiffness ECM, the activation of MAP4K4/6/7 kinases and subsequent ubiquitin phosphorylation occurs. This leads to the impairment of RNF8-mediated ubiquitin signaling and double-stranded DNA repair deficiency (Figure 3) (Deng et al., 2020).

Figure 3. Principal roles and related mechanisms of myofibroblasts-like cancer-associated fibroblasts (myCAFs) in the development of therapeutic resistance of tumors. EMT, epithelial to mesenchymal transition; ECM, extracellular matrix; DSB, double-strand break.

Another critical mechanism underlying drug resistance, facilitated by myCAFs, involves the integrin-mediated adhesion of tumor cells to ECM components, reinforcing linkages between integrins and the cytoskeleton, consequently leading to elevated formation of focal adhesions (Valdembri and Serini, 2021). The serine/threonine kinase Akt signaling pathway in cancer cells emerges as a key player in this integrin-mediated resistance mechanism. ECM proteins produced by myCAFs, such as collagens, POSTN and FN1, interact with integrins on the surface of tumor cells, thereby activating Akt signaling (Figure 3) (Elango et al., 2022; Wang et al., 2022; Sun et al., 2023). For instance, co-cultivation of ovarian cancer cells with CAFs or on the plates pre-coated with COL11A1 attenuates cisplatin-induced apoptosis (Rada et al., 2018; Nallanthighal et al., 2020). This effect is achieved by activating the Akt signaling pathway through the interaction of COL11A1 with DDR2 receptor tyrosine kinase and α1β1 integrin on the cell surface of ovarian cancer cells. In turn, Akt activates downstream NF-kB signaling, leading to the induction of the expression of three antiapoptotic proteins, including XIAP, BIRC2, and BIRC3, and decreasing levels of cleaved caspase-3 (Figure 3) (Rada et al., 2018). Moreover, Akt signaling leads to the phosphorylation of 5′ AMP-activated protein kinase and upregulates mitochondrial fatty acid oxidation, which is necessary for maintaining ovarian cancer cell survival (Figure 3) (Nallanthighal et al., 2020).

Another downstream mechanism activated by Akt leads to the upregulation of the antiapoptotic protein BCL-2 and the downregulation of proapoptotic protein BAX. Altered balance between BCL-2 and BAX suppressed the apoptotic program by reduction in cleaved caspase-3/9 expression (Figure 3). This mechanism mediates the resistance of pancreatic cancer cells cultivated on COL11A1-coated plates to gemcitabine (Wang et al., 2021) and the resistance of ovarian cancer cells exposed to recombinant POSTN or co-cultured with POSTN-overexpressing fibroblasts to cisplatin (Chu et al., 2020). Furthermore, FN1/PI3K/Akt signaling contributes to breast cancer cell resistance against docetaxel by inhibiting the ASK1/p38 apoptotic pathway (Figure 3) (Xing et al., 2008). Activation of PI3K/Akt/αvβ5 signaling axis by unfolded type III domain of FN1 protects non-small cell lung cancer cells from apoptosis induced by TNF-related apoptosis inducing ligand (Cho et al., 2016).

ECM protein-integrin binding can activate other signaling cascades besides Akt in tumor cells. For instance, FN1 binding to β1 integrin on colorectal cancer cells activates FAK/CDC42/YAP signaling, leading to upregulation of the transcription factor SOX2 and consequent resistance to 5-fluorouracil and cisplatin (Figure 3) (Ye et al., 2020). Additionally, stromal FN1 promotes both FAK/RAS/MEK/ERK and FAK/PI3K/Akt pathways in breast cancer cells, leading to estrogen receptor-α phosphorylation and subsequent tamoxifen sensitivity (Figure 3) (Pontiggia et al., 2012). Furthermore, the interaction of ECM proteins with integrins significantly impacts the activity of ATP binding cassette (ABC) transporters, which recognize cytostatic drugs and export them from the cytosol. Cultivating breast cancer cells on the microplates coated with collagen I and fibronectin leads to enhanced resistance to doxorubicin, cisplatin, and mitoxantrone, due to increased activity of ABC efflux transporters (Figure 3) (Baltes et al., 2020).

myCAFs also contribute to anti-cancer therapy resistance through mechanisms beyond ECM remodeling. For instance, myCAFs enhance proliferation, migration, and resistance to carboplatin and cisplatin in cervical squamous cell carcinoma via the NRG1/ERBB3 pathway activation (Figure 3) (Liu et al., 2023). Furthermore, the expression of the myCAF-specific gene signature correlates with poor response to anti-PD-1 immunotherapy in patients with urothelial carcinoma, melanoma, and non-small cell lung cancer, potentially mediated by myCAF-induced modulation of the immune microenvironment (Kieffer et al., 2020; Pan et al., 2023). The impact on the effectiveness of anti–PD-1 immunotherapy may be explained by the ability of myCAFs in vitro to increase the proportion of CD4⁺ CD25⁺ FOXP3⁺ Tregs among CD4⁺CD25⁺ T lymphocytes and elevate the levels of PD-1 and CTLA4 proteins on the surface of CD4⁺ CD25⁺ FOXP3⁺ Tregs (Figure 3) (Kieffer et al., 2020).

In summary, the myCAF population serves not only as a prognostic indicator but also as a promising therapeutic target. Other myCAF markers, including INHBA, SULF1, CTHRC1, VCAN, and COL5A1, have also been implicated in influencing resistance to anticancer drugs (Table 1). A significant limitation of these studies is the use of tumor cells for investigation of myCAFs markers in the development of resistance to various anti-tumor medications. Given that this gene signature is characteristic of CAFs, not tumor cells, conducting similar studies using CAFs could provide greater clarity on acquired chemoresistance in tumors.

Table 1. The role of myofibroblasts-like cancer-associated fibroblast markers in the development of therapeutic resistance of tumors.

Inflammatory subtype of cancer-associated fibroblasts—iCAFs

Gene signature of iCAF

It is widely recognized that CAFs play a crucial role in shaping the unique tumor immune microenvironment, facilitating tumor immune evasion (Mhaidly and Mechta-Grigoriou, 2021). Among the diverse CAF subtypes, iCAFs stand out for their distinct immunomodulatory secretory profile (Figure 1). iCAFs are characterized by their expression of various genes, including members of the chemokine ligand family (CXCL12 and CXCL14), the insulin-like growth factor family (IGF1 and IGFBP6), complement-regulatory genes (C3, C7, and CFD), and some other genes (APOD, FBLN1, PTGDS, DPT, and GSN) (Elyada et al., 2019; Zhang et al., 2020; Chen et al., 2020; Wang et al., 2021; Galbo et al., 2021; Pu et al., 2021; Li et al., 2022; Chen et al., 2022; Li et al., 2022; Hu et al., 2022; Loret et al., 2022; Obradovic et al., 2022; Yang et al., 2022; Liu et al., 2023; Cords et al., 2023; Ma et al., 2023; Pan et al., 2023; Werba et al., 2023).

The functions attributed to iCAFs encompass a broad spectrum, ranging from involvement in inflammatory responses and complement cascades to mediating cytokine-driven signaling and fostering cancer cell proliferation. Unlike myCAFs, iCAFs are located more distant from cancer cells (Öhlund et al., 2017; Wu et al., 2020). It has also been shown that iCAFs encircle vCAFs and the endothelial cells lining the tumor blood vessels (Cords et al., 2023). Notably, the induction of the iCAF phenotype predominantly occurs through the IL1-IL1R1 axis and can occur independently of direct contact with cancer cells (Biffi et al., 2019), leading researchers to frequently refer to them as IL1+ CAFs in scientific investigations (Dominguez et al., 2020; Hornburg et al., 2021).

Prognostic potential of iCAFs markers

Based on scRNA-seq data, iCAFs, as well as myCAFs, exhibit a distinct gene signature, enabling their differentiation from other tumor cell populations (Lambrechts et al., 2018; Chen et al., 2020; Wang et al., 2021; Luo et al., 2022; Liu et al., 2023; Qin et al., 2023; Wang et al., 2023). Consequently, alterations in the expression of this gene signature within tumor tissues are indicative of shifts in the abundance of iCAFs. Unlike myCAFs markers, markers associated with iCAFs tend to exhibit significant downregulation at the transcriptional level in tumor tissue compared to normal tissue across various cancer types (Figure 4; Supplementary Table S3). However, an exception to this trend is observed in pancreatic cancer, where the expression of most iCAF markers notably increases in tumor tissue (Figure 4; Supplementary Table S3). Additionally, the expression of certain genes correlates with overall survival across different tumor types (Figure 4; Supplementary Table S4).

Figure 4. Changes in the expression and prognostic significance of inflammatory cancer-associated fibroblasts (iCAFs) markers across different types of tumors. Red indicates increased expression of the gene/protein in the tumor compared to normal tissue, blue indicates decreased expression, and purple indicates both increased and decreased expression observed in different studies. A cross symbol indicates an association of increased gene expression with poor prognosis, while a checkmark indicates an association with good prognosis.

Similar to myCAFs, iCAFs are also mentioned in the context of disease prognosis; however, these findings are contradictory. Higher iCAF abundance has been associated with poor clinical outcomes and diminished response to immunotherapy in patients with bladder cancer, low-grade glioma, and head and neck squamous cell carcinoma (Galbo et al., 2021; Chen et al., 2022; Obradovic et al., 2022; Mou et al., 2023). In colorectal cancer, increased abundance of only the IL1R1+ iCAF subgroup, but not all other iCAFs, correlates with a lower overall survival rate (Koncina et al., 2023). Conversely, in pancreatic ductal adenocarcinoma, a higher iCAF abundance is linked to better prognosis and improved response to immunotherapy (Hu et al., 2022). These contradictory observations suggest that the presence of iCAFs in tumors and their impact on tumor behavior vary depending on the specific tumor type.

Contribution of iCAFs to the development of chemoresistance

Due to increased expression of inflammatory cytokines, iCAFs induce the differentiation of immune cells into pro-tumor populations and reduce the activity of immunostimulating cells, collectively contributing to the establishment of immunosuppressive TME. Across various tumor types, scRNA-seq studies consistently demonstrate that iCAFs contribute to the differentiation of macrophages towards an alternatively activated M2-like phenotype (Chen et al., 2020; Chen et al., 2022; Ma et al., 2023; Werba et al., 2023). This phenomenon is supported by the fact that cytokines typically produced by iCAFs play a pivotal role in macrophage polarization. For instance, in prostate, non-small cell lung, and colorectal cancers, CAF-derived CXCL12 and CXCL14 facilitate the M2 polarization of macrophages (Figure 5) (Augsten et al., 2014; Comito et al., 2014; Wu et al., 2022). M2 macrophages, distinct from classically activated (M1) ones, promote tumor proliferation, invasion, and immune suppression. Furthermore, M2-like macrophages can confer therapeutic tolerance to various anticancer drugs, including cisplatin, gemcitabine, tamoxifen, and doxorubicin (Wang et al., 2024). For example, CAF-derived CXCL12 accelerates colorectal cancer progression and induces cisplatin resistance in vivo by promoting the M2 polarization of macrophages (Figure 5) (Jiang et al., 2023).

Figure 5. Principal roles and related mechanisms of inflammatory cancer-associated fibroblasts (iCAFs) in the development of therapeutic resistance of tumors. EMT, epithelial to mesenchymal transition.

In scRNA-seq studies, direct interactions between iCAFs and T cells have also been elucidated. iCAFs are presumed to interact with various tumor-infiltrating T cell populations through chemokine ligand-receptor interactions (Wu et al., 2020; Pu et al., 2021; Li et al., 2022). In triple-negative breast cancer, CXCL12+ iCAFs induce CD8⁺ T cell dysfunction (Figure 5) (Wu et al., 2020). Notably, the iCAFs signature exhibits a significant positive correlation with the exhausted CD8⁺ T cell signature but a negative correlation with cytotoxic CD8⁺ T cells in head and neck squamous cell carcinoma (Figure 5) (Mou et al., 2023). Cytotoxic CD8⁺ T cells are recognized as the most potent effectors in the anticancer immune response, forming the basis of current successful cancer immunotherapies (Raskov et al., 2021). Conversely, dysfunction and exhaustion of CD8⁺ T cells diminish the potential for sustained responses to checkpoint blockade (McGoverne et al., 2020).

In addition to modulating the tumor immune microenvironment, iCAFs exert direct effects on cancer cells, promoting resistance to anti-cancer therapy. Co-cultivation experiments involving ovarian, colorectal, and pancreatic cancer cells with CAFs or CAF supernatants have demonstrated a reduction in cisplatin- and gemcitabine-induced apoptosis, attributed to CAF-derived CXCL12 (Zhang et al., 2015; Morimoto et al., 2016; Wei et al., 2018; Zhang et al., 2020; Jiang et al., 2023). CXCL12-induced resistance primarily occurs via activation of the CXCL12/CXCR4 axis, initiating downstream signaling cascades in tumor cells, including Akt, ERK, and Wnt/β-catenin pathways (Figure 5) (Singh et al., 2010; Zhang et al., 2015; Zhang et al., 2020). These pathways regulate the expression of mitochondrial apoptotic proteins, such as BCL-2 and BAX. Reduced BAX/BCL-2 ratio in tumor cells leads to the inhibition of downstream caspase 3, which drives the terminal events of apoptosis. In colorectal cancer, CXCL12/CXCR4-mediated upregulation of miR-125b initiates a similar cascade to evade the effects of 5-fluorouracil (Yu et al., 2017). It is worth noting that a comparable mechanism of resistance to the cytotoxic effects of chemotherapeutic agents was observed in the interaction between myCAF-specific proteins and tumor cells. Suppressing effector caspases (caspase-3 and 9) may also occur upon activation of the CXCL12/CXCR4/survivin axis, resulting in decreased apoptosis and enhanced radiotherapy resistance in colon cancer cells (Figure 5) (Wang et al., 2017). Furthermore, the IL-6 autocrine loop, facilitated by Akt and ERK signaling pathway activation, contributes to CXCL12-induced gemcitabine chemoresistance in pancreatic cancer cells (Zhang et al., 2015). Additionally, CXCL12/CXCR4 signaling antagonizes docetaxel-induced G2/M phase cell cycle arrest by activating PAK4/LIMK1, enhancing microtubule dynamics (Figure 5). Consequently, this impedes docetaxel-mediated microtubule stabilization, suppresses its anti-mitotic effect, and promotes tumor cell survival (Bhardwaj et al., 2014). Collectively, these findings underscore the role of the CXCL12 axis in mediating cancer chemoresistance.

Less explored in the context of anticancer drug resistance, other iCAF markers warrant further investigation (Table 2). It is known that CAF-derived CXCL14 activates p38/STAT1 signaling in breast cancer cells, reducing paclitaxel-induced apoptosis (Figure 5) (Liu et al., 2017). Insulin-like growth factor IGF1 and insulin-like growth factor binding protein IGFBP6 exert contrasting effects on tumor cells, with pro-tumor and anti-tumor effects, respectively (Figure 5). Depending on the balance between secreted IGF and IGFBP proteins, CAFs can induce both osimertinib resistance and osimertinib sensitivity in lung cancer cells (Remsing Rix et al., 2022). Regarding complement system genes C3 and C7, there exists only indirect evidence suggesting their potential impact on anticancer therapy resistance. Elevated C7 expression predicts an unfavorable prognosis in patients treated with taxane-anthracycline chemotherapy (Zhang et al., 2021), while C3 expression is associated with resistance to 5-fluorouracil- and oxaliplatin-based chemotherapy in colorectal cancer (He et al., 2021). Consequently, the precise role of the iCAFs specific signature in tumor cell resistance to therapeutic agents remains incompletely characterized. A comprehensive investigation of iCAF markers could elucidate the contribution of this population to tumor resistance development.

Table 2. The role of inflammatory cancer-associated fibroblast markers in the development of therapeutic resistance of tumors.

Antigen-presenting subtype of cancer-associated fibroblasts—apCAFs

One of the pivotal mechanisms enabling tumors to evade immune surveillance involves attenuating the initiation of anti-tumor T-cell responses mediated by antigen-presenting cells (APCs). Within the TME, APCs, predominantly constituted by “professional” APCs including dendritic cells (DCs), macrophages, and B cells, orchestrate the activation of anti-cancer immunity (Wilke et al., 2011; Martin et al., 2015). Nonetheless, the initiation and regulation of anti-cancer immunity may also involve “non-professional” APCs, such as innate lymphoid cells, epithelial cells, endothelial cells, mast cells, granulocytes or fibroblasts (Kambayashi and Laufer, 2014; Park et al., 2022). Identified through scRNA-seq analysis of pancreatic tumors from mice, apCAFs represent a transcriptionally and functionally distinct CAF subtype, characterized by heightened expression of genes associated with MHC class II (MHC II)-mediated antigen presentation (Elyada et al., 2019). Subsequently, the presence of a separate apCAF population was confirmed by scRNA-seq data across more than 10 different types of human tumors (Zhang et al., 2020; Kieffer et al., 2020; Wang et al., 2021; Hu et al., 2022; Luo et al., 2022; Liu et al., 2023; Cords et al., 2023). The key genes that differentiated apCAFs from other tumor fibroblast subtypes in these studies include HLA-DRA (encoding MHC II alpha chain), HLA-DRB1 (encoding MHC II beta chain) and CD74 (encoding MHC II invariant chain). These genes underscore the involvement of apCAFs in critical biological processes such as antigen processing and presentation, allograft rejection, and inflammatory response.

While ex vivo experiments validated the capacity of apCAFs to present model antigens to CD4⁺ T cells (Elyada et al., 2019), their precise role within the TME remains ambiguous and, to a large extent, contradictory. “Professional” APCs and other MHC II-expressing tumor cells contribute to the initiation and maintenance of anti-tumor immunity through interaction with tumor-specific CD4⁺ T cells (Harryvan et al., 2021; Tay et al., 2021). To provoke the activation, proliferation and differentiation of T cells, APCs must present two signal molecule groups on their surface: MHC II molecules and costimulatory molecules like CD80, CD86, and CD40 (Liao et al., 2019). In turn, apCAFs, like other subtypes of CAFs, exhibit low expression of costimulatory molecules, hindering the full activation of T cells (Elyada et al., 2019; Friedman et al., 2020). However, in pancreatic cancer, apCAFs originating from the mesothelium have been implicated in inducing the transformation of naïve CD4⁺ T cells into FOXP3+ regulatory T cells in an antigen-specific manner, thereby fostering immune evasion within the tumor milieu (Huang et al., 2022). Conversely, in human lung non-small cell carcinomas, apCAFs have displayed tumor-suppressive properties (Kerdidani et al., 2022). apCAFs have been shown to directly activate effector CD4⁺ T cells infiltrating tumors through MHC II-mediated T-cell receptor stimulation. Additionally, the interaction between the ligand C1q, secreted by apCAFs, and the C1qbp receptor on the surface of effector CD4⁺ T cells confers protection of the latter against apoptosis. Conversely, targeted deletion of MHCII or C1q in fibroblasts markedly accelerates tumor growth.

scRNA-seq analysis has revealed a substantial upregulation of genes associated with the response to IFNγ in the apCAFs population (Zhang et al., 2020; Kieffer et al., 2020; Cords et al., 2023). Hence, the impact of IFNγ, purportedly secreted by T helper 1 cells, cytotoxic T lymphocytes, and natural killer cells (Gocher et al., 2022), likely stimulates the induction of the apCAF phenotype in tumors. Notably, apCAFs are predominantly detected in tumors expressing IFNγ. This assertion finds support in experiments where the injection of lung cancer cells lacking IFNγ/IFNγR into mice resulted in a significant downregulation of MHC II expression in CAFs (Kerdidani et al., 2022). Additionally, in pancreatic cancer, mesothelial cells have been identified as a source of apCAFs, undergoing a transition activated by signaling cascades involving IL-1 and TGFβ (Huang et al., 2022). scRNA-seq analysis suggests that the apCAFs population may represent a transitional state between tumor-associated macrophages and myofibroblasts (Luo et al., 2022).

In conclusion, the existence of a distinct subset of antigen-presenting CAFs, characterized by heightened expression of MHC II-associated genes within the tumor stromal microenvironment, is well-established. However, further elucidation of the conditions governing their activation and functional significance is imperative.

Other subtypes of cancer-associated fibroblasts

In addition to the three primary populations of CAFs, scRNA-seq studies have unveiled several other subgroups (Figure 1). For instance, among the datasets, a distinct cluster of proliferative CAFs (pCAFs) or dividing CAFs (dCAFs) has been identified (Galbo et al., 2021; Li et al., 2022; Cords et al., 2023; Ma et al., 2023). These cells exhibit unique expression patterns of cell cycle-related genes (TOP2A, TUBA1B, and MKI67). Another cluster, termed interferon-response CAFs (ifnCAFs), is characterized by elevated expression of a set of IFNα and IFNγ response genes (IFIT1, IFIT2, IFIT3, CXCL11, and others) (Kieffer et al., 2020; Cords et al., 2023). Imaging Mass Cytometry analysis has shown that ifnCAFs are localized in close proximity to tumor cells (Cords et al., 2023). In vitro models have demonstrated that ifnCAFs exert a proliferative effect on MCF-7 breast cancer cells (Hosein et al., 2015). Conversely, the impact of effector CD8⁺ T cell-derived IFNγ on CAFs from ovarian tumors stimulates the expression of GGT5 and leads to a reduction in glutathione levels in the fibroblast medium. Consequently, CAFs lose their ability to protect tumor cells from the cytotoxic effects of cisplatin, thereby enhancing therapeutic effectiveness (Wang et al., 2016). In a pan-cancer study, a cluster of metabolic CAFs (meCAFs) has been identified, associated with the response to hypoxia, glycolysis, and alanine, aspartate, and glutamate metabolism (Ma et al., 2023). Patients with pancreatic ductal adenocarcinoma exhibiting a high abundance of meCAFs faced an elevated risk of metastasis and an unfavorable prognosis; nevertheless, they demonstrated a remarkably improved response to immunotherapy (Wang et al., 2021). During scRNA-seq analysis of intrahepatic cholangiocarcinoma, two additional unique clusters of CAFs were identified: EMT-like CAFs, expressing high levels of epithelium-specific genes (KRT19, KRT8, and SAA1), and lipofibroblasts with increased expression of lipid metabolism genes (APOA2, FABP1, FABP4, and FRZB) (Zhang et al., 2020). In breast tumors, two additional rare populations have been identified: tumor-like CAFs (tCAFs) and reticular-like CAFs (rCAFs) (Cords et al., 2023). The first population is characterized by elevated expression of proliferation, migration, and metastasis-associated genes (PDPN, MME, TMEM158, and NDRG1), while markers of the second population coincide with those of reticular fibroblasts in lymphoid tissues (CCL21 and CCL19).

Thus, the classification of CAFs remains complex, and the exact number of distinct CAF populations is still unknown. Currently, a few rare CAF populations can be identified using scRNA-seq methods on ex vivo data in certain tumor types. Discrepancies in research findings may be attributed to the existence of unique populations within specific tumor types or even among patients. Furthermore, fibroblast populations can transition from one to another, for example, from iCAFs to myCAFs (Öhlund et al., 2017), altering the number and representation of CAF populations throughout tumor progression. Challenges in identifying CAF populations in studies may also stem from the specificities of scRNA-seq analysis. For instance, some rare populations may go undetected due to the limited amount of analyzed material. Additionally, scRNA-seq analysis allows for the segmentation of all cells into an arbitrarily large number of clusters. Consequently, it is challenging to determine whether the identified clusters correspond to unique, rare CAF phenotypes or are solely related to analysis features and inaccuracies.

Discussion

Despite the long-standing history of researching CAFs, the precise classification of individual populations remains a formidable challenge in the scientific community. While scRNA-seq technologies aid in unraveling the heterogeneity of CAFs, several unresolved issues persist. Presently, the existence of three primary CAF populations is firmly established: myCAFs, iCAFs, and apCAFs. While the characteristics of iCAFs and apCAFs demonstrate consistency across various studies, notable discrepancies emerge concerning myCAFs. Depending on the study, the definition of myCAFs encompasses two cellular populations with completely different transcriptional profiles. The distinctive features of one of these populations (RGS5+MYH11+ cells) overlap with the characteristic traits of pericytes. We propose a systematic approach for CAF classification: Firstly, during the analysis of RGS5+MYH11+ cells, it is imperative to confirm their fibroblastic nature and exclude pericytic identity. If confirmed as fibroblasts, we advocate referring to them as vCAFs, aligning with prior studies that distinguish pericytes from RGS5+MYH11+ CAFs (vCAFs) (Cords et al., 2023). On the other hand, myCAFs can be defined as fibroblasts actively expressing ECM genes. Such a classification strategy serves to prevent misinterpretation and ensures accurate characterization, particularly regarding pericyte misidentification.

In addition to the three primary populations, scRNA-seq technologies offer the capability to identify rare and low-abundance CAF populations across diverse tumor types (Zhang et al., 2020; Galbo et al., 2021; Li et al., 2022; Cords et al., 2023; Ma et al., 2023). Achieving a comprehensive and accurate classification of all conceivable CAF populations necessitates the confirmation of their existence in vivo. Moreover, it is imperative to ascertain whether these populations are universally present across tumor types but have remained undetected due to their scarcity, or if they are exclusive to specific tumor types. A thorough characterization of all CAF populations entails investigating activation mechanisms, reciprocal transitions between distinct subpopulations, and their spatial distribution within the TME. Our understanding of how these functional subsets evolve as tumors progress and metastasize to distant sites remains incomplete. It is important to understand that as the tumor advances, the abundance of certain CAF populations and their contributions to carcinogenesis may undergo dynamic changes. Furthermore, specific rare CAF populations identified through scRNA-seq analysis may directly correlate with tumor stage. Given that each CAF population plays a distinct role in cancer development, addressing these complexities holds promise for driving significant advancements in tumor diagnosis, treatment, and monitoring methodologies.

Given the role of CAFs in conferring resistance to chemotherapy through ECM remodeling, tumor cell proliferation promotion, and immune response suppression via secreted molecules, novel treatment avenues emerge. Therapeutic strategies targeting CAFs can be categorized into three main approaches: 1) development of agents directly targeting CAF surface markers (primarily ACTA2 and FAP); 2) inhibition of signaling pathways implicated in CAF activation (such as TGFβ); 3) targeting CAF-derived ECM proteins (Zhang et al., 2023). However, many preclinical studies have not observed significant anti-tumor effects or notable improvements in patient survival (Zhang et al., 2023). The clinical shortcomings of CAF-targeted therapy may stem from several factors. Firstly, the toxicity of current drugs largely results from the non-specificity of target existing proteins. Notably, CAF surface markers ACTA2 and FAP are expressed by other cells within the tumor microenvironment, undermining the precision of CAF-based therapeutic strategies (Kazakova et al., 2022). Additionally, not all CAFs express ACTA2 and FAP, further complicating the efficacy of CAF-targeted therapy. Secondly, the majority of ongoing preclinical trials focus on the entire CAF population, disregarding their heterogeneous nature and multifaceted functions within tumors (Zhang et al., 2023). As distinct CAF populations may exhibit both tumor-promoting and tumor-suppressive properties, targeting specific pro-tumoral CAF populations proves challenging. Reprogramming the phenotype of CAFs could potentially offer a more effective strategy. Nonetheless, the development of such therapeutic agents necessitates a clear understanding of which CAF populations in tumors exclusively possess tumor-suppressive properties. When devising clinically effective anti-CAF therapy with minimal systemic side effects, it is crucial to acknowledge the unique cellular composition of individual tumors, characterized by specific ratios of CAF populations. We anticipate that novel therapeutic approaches will emerge by reprogramming pro-tumor CAFs into an anti-tumor CAF population. Implementing such agents as first-line treatments holds promise for enhancing the efficacy of conventional chemotherapeutic drugs.

Author contributions

AK: Conceptualization, Visualization, Writing–original draft, Writing–review and editing. ML: Funding acquisition, Writing–original draft, Writing–review and editing. KA: Conceptualization, Supervision, Writing–review and editing. IB: Writing–original draft, Writing–review and editing. OI: Writing–review and editing. PS: Writing–review and editing. AS: Writing–review and editing. GA: Conceptualization, Funding acquisition, Supervision, Writing–review and editing. VS: Conceptualization, Funding acquisition, Supervision, Writing–review and editing.

Funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work was supported by the Russian Science Foundation project no. 22-75-00103 (AK, PS, and ML) and by grant 075-15-2019-1669 from the Ministry of Science and Higher Education of the Russian Federation (AK, PS, OI, ML, VS, and GA).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcell.2024.1403122/full#supplementary-material

References